Alpha Tau Medical Ltd., (DRTS) News
Filter DRTS News Items
DRTS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DRTS News Highlights
- For DRTS, its 30 day story count is now at 2.
- Over the past 15 days, the trend for DRTS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC are the most mentioned tickers in articles about DRTS.
Latest DRTS News From Around the Web
Below are the latest news stories about ALPHA TAU MEDICAL LTD that investors may wish to consider to help them evaluate DRTS as an investment opportunity.
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials - - The Company will also be featured at the Biotech Showcase™ occurring in parallel, and will host institutional investor meetings at both conferences - JERUSALEM, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or |
Sidoti Events, LLC's Virtual December Small-Cap ConferenceNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ... |
Alpha Tau to Participate in Sidoti Small-Cap ConferenceJERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will present at the Sidoti Small-Cap Virtual Conference on Thursday, December 7th, 2023. Format:Presentation and 1-on-1 meetingsDate:December 7th, 2023Time:9:15 AM ETLocation:VirtualRegistration:https://sidoti.zoom.us/webinar/register/WN_VNDWwCEtSeySoAVKVx38YQ About Al |
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events - - First five patients received conservative partial tumor coverage, and in patients with higher radium-224 levels, increased tumor responses were observed, with the last three patients presenting two stable disease responses and one partial response at last measurement - JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical |
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck CancerJERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare investment, development and commercialization platform which is partnered with Alpha Tau, announced today that Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in pat |
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underway in Montreal, Canada - - 89% CR, two-year local recurrence-free survival of 77%, and no treatment-related grade 2 or higher late-onset toxicity reported from an analysis of four feasibility trials in 71 patients with unresectable skin and head and neck cancers - - Former U.S. FDA Commissioner, Step |
Alpha Tau to Participate in November Investor ConferencesJERUSALEM, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences in November 2023. Event:Emerging Growth ConferenceFormat:Company presentation and 1-on-1 meetingsDate:Thursday, November 2nd, 2023Time3:25 – 3:35 PM ETLocation:Virtual Event:Jefferies London Healthcare ConferenceFo |
Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register NowMIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting |
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing FacilityJERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its U.S. subsidiary, Alpha Tau Medical Inc., has entered into a long-term lease agreement for a standalone building of over 14,000 rentable square feet in Hudson, New Hampshire, with the intention of erecting the Company’s second U.S. manufacturing site, alongside its first site |
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory BoardJERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board. A distinguished expert in the field of radiation oncology and translational/clinical research, and a renowned physician, Dr. Hahn brings a wealth |